One chart, one registry, one structural read of the U.S. dietary supplement market. All counts pulled live from the NIH Office of Dietary Supplements Dietary Supplement Label Database (dsld.od.nih.gov) on 2026-05-25. Status=1 (currently on-market) subset only.
The chart
What the distribution actually shows
Across the entire on-market subset of the NIH DSLD on 2026-05-25, there are 4,943 distinct active ingredients (after filtering nutrition-facts panel tokens like "calories", "protein", "sodium" that DSLD treats as ingredients but are really FDA-mandatory disclosures). Each one is carried by some number of distinct brands. The shape of that distribution is the whole story.
| Brands carrying ingredient | Ingredients in bucket | % of all on-market ingredients |
|---|---|---|
| 1 | 0 | 0.0% |
| 2 | 0 | 0.0% |
| 3–5 | 528 | 10.7% |
| 6–10 | 1,729 | 35.0% |
| 11–25 | 1,421 | 28.7% |
| 26–50 | 612 | 12.4% |
| 51–100 | 356 | 7.2% |
| 101–250 | 222 | 4.5% |
| 251–500 | 62 | 1.3% |
| 501+ | 13 | 0.3% |
| Total | 4,943 | 100% |
Three structural reads:
- The mode is 6–10 brands. 35% of all on-market active ingredients are carried by 6 to 10 distinct brands. That is the modal "specialty ingredient" — small enough that the ingredient supplier knows every account by name; large enough that adoption is validated by independent formulators.
- The long tail (3–25 brands) holds 74% of ingredients. Adding the 11–25 bucket, three quarters of all active ingredients on the U.S. supplement shelf are carried by 25 or fewer brands. For an ingredient supplier with a differentiated form, dose, or sourcing story, this is where the leverage lives — single-digit numbers of buyer accounts per ingredient.
- The saturated head is tiny. Only 75 ingredients (1.5%) are carried by 250 or more brands. Only 13 (0.3%) reach the 500+ bucket. The "everyone has it" tier of the supplement market is vanishingly small.
What's actually in the saturated head?
The ten ingredients with the highest brand counts on-market — i.e., the leftmost 1% of the distribution above — are:
| Rank | Ingredient | Brands carrying (on-market) |
|---|---|---|
| 1 | Docosahexaenoic acid (DHA) | 773 |
| 2 | Eicosapentaenoic acid (EPA) | 703 |
| 3 | Inositol | 679 |
| 4 | Bromelain | 656 |
| 5 | Boron | 642 |
| 6 | L-theanine | 625 |
| 7 | Grape seed extract | 584 |
| 8 | L-tyrosine | 583 |
| 9 | L-glutamine | 568 |
| 10 | Lipase (digestive enzyme) | 553 |
This top-10 is structurally interesting: omega-3 fatty acids (DHA + EPA) sit at the top, followed by amino-acid derivatives (inositol, L-theanine, L-tyrosine, L-glutamine), botanical extracts with strong claim anchors (bromelain for inflammation, grape seed for antioxidant, boron for bone), and digestive enzymes (lipase). These are the ingredients where "every brand has a SKU" is genuinely true.
The 0% at the head of the distribution is real
The chart shows zero ingredients carried by exactly 1 or 2 brands. That's not a data gap; it's the data shape. Ingredients that make it onto an on-market label in the U.S. supplement market almost always hit at least 3 brands — formulators draw from common ingredient catalogs, and the ones that don't propagate at least that far tend to get pulled from the registry before they show up as on-market. The distribution starts at 3 and walks down a long tail.
What this means commercially
For an ingredient supplier, the asymmetry is the opportunity. If your ingredient is in the 3–25-brand range — which is where three quarters of all ingredients live — your total addressable buyer count is small enough that the right sales motion is account-by-account, not lead generation. Knowing which 8 brands carry your ingredient (and which 200 brands carry an adjacent one and are plausible targets to add it) is the entire B2B sales motion.
For a brand R&D team, the same distribution tells you the inverse: when you're considering adding an ingredient, look up where it sits on this curve. An ingredient in the saturated head is commoditized — easy to source, no differentiation. An ingredient in the long tail is novel — harder to source, but actually distinguishing on a label.
For investors looking at supplement-ingredient businesses, the distribution sets the realistic ceiling on how broadly any one ingredient can scale. Reaching the 250+ brand bucket is rare; reaching 500+ is exceptional. The investable thesis is rarely "this ingredient will saturate" — it's "this ingredient will move up several brand-count tiers."
Methodology
The chart and tables on this page are pulled from a single ES
aggregation against the NIH DSLD on-market subset (status=1) on
2026-05-25. We do a terms aggregation on the multi-valued
ingredient_names field with a brand-id cardinality sub-agg
and bucket the resulting brand counts. Nutrition-facts panel tokens
(calories, protein, sodium, etc.)
are filtered post-aggregation — they appear in DSLD as ingredient
strings because FDA 21 CFR §101.36 requires their disclosure, but
they're not active ingredients in the commercial sense.
The same per-ingredient on-market / off-market split that produces this curve is available row-by-row on the Knitify Radar's Ingredient Buyer Prospects board (sales-ready brand list for any ingredient you specify) and the Ingredient Profile board (co-formulation, brand-peer, claim, form, and country panels — all with the on/off-market stacked-bar split applied per bucket as of 2026-05-26).
Editorial commentary on publicly available NIH Office of Dietary Supplements data. Not investment, legal, regulatory, or medical advice. Forward-looking statements are qualitative observations of public-data trends, not predictions.